TissueLabs

Executive Summary

TissueLabs is a Swiss biotech company revolutionizing tissue engineering by offering researchers, scientists, and medical innovators cutting-edge platforms to design and fabricate functional human-like tissues. Founded in 2019 and headquartered in Zurich, the company provides advanced bioprinters, biomaterials, and ready-to-use tissue engineering kits to academia, pharmaceutical companies, and research institutions. These tools are designed to accelerate breakthroughs in drug discovery, disease modeling, and regenerative medicine, potentially reducing reliance on animal testing and streamlining preclinical development. By democratizing access to complex tissue fabrication, TissueLabs aims to become a key enabler in the rapidly growing tissue engineering market.

Upcoming Catalysts (preview)

• Q2 2026Launch of next-generation bioprinter with enhanced precision and throughput70% success
• Q3 2026Strategic partnership with a top-20 pharmaceutical company for drug screening applications50% success
• Q4 2026Series A funding round to scale manufacturing and expand commercialization60% success